The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine/naloxone combination) prevent a patient from experiencing withdrawal symptoms but allow the patient to still experience a limited “high” without taking any illicit opioids. Abstinent therapies (i.e., naltrexone) block the euphoric effect of opioids if a patient attempts to take an illicit opioid while on abstinent therapy. In most markets, regardless of which type of opioid addiction treatment received, relapse rates among opioid addicts remain high. Thus, commercial opportunity exists for new opioid addiction treatments, particularly those that can more effectively reduce the craving and opioid use and do not have an abuse potential.

Questions Answered:

  • How is opioid addiction currently treated in the major pharmaceutical markets? What are interviewed experts’ opinions of current opioid addiction therapies?
  • What are the greatest unmet needs in terms of treating opioid addiction and to what extent will these needs be fulfilled in the next ten years?
  • What do interviewed experts think about late-phase emerging therapies such as long-acting depot buprenorphine products from Camurus/Braeburn Pharmaceuticals (CAM-2038) and Indivior (RBP-6000)?
  • What is the commercial potential of late-phase pipeline products in the opioid addiction market should they launch?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Opioid Addiction - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • December 2017
      • Executive Summary
        • Key Findings
          • Market Share of Opioid Addiction Drug Classes: 2016
          • Market Share of Opioid Addiction Drug Classes: 2026
          • Opioid Addiction SWOT Analysis
      • Market Outlook
        • Key Findings
          • Expert Insight
          • Market Overview
          • Opioid Addiction Regional Sales (All Populations) in the Major Pharmaceutical Markets
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Opioid Addiction?
          • What Factors Are Constraining the Market for Opioid Addiction?
          • Key Market Events for Opioid Addiction: 2016-2026
          • Major-Market Share of Brand and Generic Sales in Opioid Addiction, 2016-2026
          • Major-Market Brand and Generic Patient Share in Opioid Addiction, 2016-2026
        • Drug-Class-Specific Trends
          • Major-Market Sales of Opioid Receptor Agonists in Opioid Addiction, 2016-2026
          • Major-Market Patient Share of Non-Depot Opioid Receptor Agonists in Opioid Addiction, 2016-2026
          • Major-Market Patient Share of Buprenorphine Depots in Opioid Addiction, 2018-2026
          • Major-Market Sales of Opioid Receptor Antagonists in Opioid Addiction, 2016-2026
          • Major-Market Patient Share of Opioid Receptor Antagonists in Opioid Addiction, 2016-2026
      • Forecast
        • Sales of Drugs to Treat Opioid Addiction in the Major Pharmaceutical Markets: 2016-2026
      • Etiology and Pathophysiology
        • Key Findings
          • Expert Insight
          • Disease Overview
          • DSM-5 Characterization of Opioid Use Disorder
        • Disease Characteristics and Addiction Pathophysiology
          • Opioid Description
          • Biological Activity and Effects of Opioid Addiction
        • Stages of Addiction
          • Stages of Addiction and Underlying Mechanisms
        • Key Pathways and Drug Targets
          • Key Brain Regions of the Dopamine Mesocorticolimbic Pathways
          • Key Neurotransmitters Mediating Natural Rewards and Drugs of Abuse
      • Epidemiology Overview
        • Key Findings
          • Expert Insight
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Total Prevalence of Opioid Disorders
          • Total Prevalent Cases of Opioid Addiction: 2016-2026 (thousands)
          • Sources Used for Diagnosed Prevalent Cases of Opioid Addiction
          • Diagnosed Prevalent Cases (Thousands)
          • Sources Used for Drug-Treated Prevalent Cases of Opioid Addiction
          • Drug-Treated Opioid Addiction Cases (Thousands)
      • Current Treatment Overview
        • Key Findings
          • Expert Insight
        • Treatment Goals
          • Key End Points Used in Clinical Trials for Opioid Addiction
          • Key Physician Insights on Clinical End Points
        • Key Current Therapies
          • Overview
          • Mechanism of Action of Key Current Drug Classes Used for Opioid Addiction
          • Current Treatments Used for Opioid Addiction
          • Advantages and Disadvantages of Methadone
          • Expert Insight: Methadone
          • Advantages and Disadvantages of Buprenorphine
          • Expert Insight: Buprenorphine
          • Advantages and Disadvantages of Buprenorphine/Naloxone
          • Expert Insight: Buprenorphine/Naloxone
          • Advantages and Disadvantages of Naltrexone
          • Expert Insight: Naltrexone
          • Advantages and Disadvantages of Vivitrol
          • Expert Insight: Vivitrol
        • Medical Practice
          • Overview
          • Treatment Guidelines
          • Country-Specific Opioid Addiction Treatment Guidelines
          • Drug Selection
          • Factors Influencing Drug Selection in Opioid Addiction
          • Treatment Decision Tree for Opioid Addiction: United States
          • Treatment Decision Tree for Opioid Addiction: Europe
          • Treatment Decision Tree for Opioid Addiction: Japan
      • Unmet Need Overview
        • Introduction
          • Key Findings
          • Expert Insight
        • Attainment of Unmet Needs
          • Current Attainment of Unmet Needs in Opioid Addiction
          • Future Attainment of Unmet Needs in Opioid Addiction
          • Top Unmet Needs in Opioid Addiction—Current and Future Attainment
          • Expert Insight on Opioid Addiction Unmet Needs
      • Emerging Therapies Overview
        • Key Findings
          • Pipeline Trends in Opioid Addiction
        • Key Emerging Therapies
          • Notable Developments Among Key Emerging Therapies for Opioid Addiction
          • Key Emerging Therapies in Development for Opioid Addiction
          • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Opioid Addiction
          • RBP-6000 Profile
          • RBP-6000 Clinical Development
          • Key Development Milestones for RBP-6000 in the Treatment of Opioid Addiction
          • Expectations for Launch and Sales Opportunity of RBP-6000 in Opioid Addiction
          • CAM-2038 Profile
          • CAM-2038 Clinical Development
          • Key Development Milestones for CAM-2038 in the Treatment of Opioid Addiction
          • Expectations for Launch and Sales Opportunity of CAM-2038 in Opioid Addiction
          • Expert Insight: Use of Buprenorphine Depots in the Treatment of Opioid Addiction
          • Expert Insight: Buprenorphine Depots
          • Likely Uses of Buprenorphine Depots for the Treatment of Opioid Addiction
        • Early-Phase Pipeline Analysis
          • Notable Developments in the Early-Phase Pipeline for Opioid Addiction
          • Select Compounds in Early-Phase Development for Opioid Addiction
      • Access & Reimbursement Overview
        • Region-Specific Reimbursement Practices
          • Key Market Access Considerations in Opioid Addiction: United States
          • General Reimbursement Environment: United States
          • Key Market Access Considerations in Opioid Addiction: EU5
          • General Reimbursement Environment: EU5
          • Key Market Access Considerations in Opioid Addiction: Japan
          • General Reimbursement Environment: Japan
      • Methodology
        • Bottom-Up Forecasting Overview
          • Patient Populations
          • Drug-Specific Assumptions
        • Bottom-Up Forecast Assumptions
          • General Sources of Data
          • General Statements About Pricing
          • Sources for Drug Prices
          • 2016 Exchange Rates
          • Dosing, Days of Therapy, and Compliance
          • Generic Erosion
          • Out-Year Forecasting
          • Emerging Therapy Prices
        • Primary Market Research
          • Experts Interviewed
      • Appendix
        • Key Abbreviations Related to Opioid Addiction
        • Brands, Marketers, and Generic Availability of Key Therapies for Opioid Addiction: by Market
        • Opioid Addiction Bibliography

    Author(s): Angela Sparrow, Ph.D.

    Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain.

    Dr. Sparrow holds a Ph.D. in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.